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Objectives: Ethnic minorities with critical limb ischemia (CLI) have historically done worse compared to Caucasians in regards to amputation risk reduction and amputation-free survival (AFS) after peripheral vascular interventions. This analysis was performed to determine whether this CLI precedent also extended to injections of concentrated bone marrow aspirate (cBMA) to the affected limb of patients without a revascularization option.
Methods: The treatment arm of the randomized, double-blind, multicenter MOBILE trial was stratified by ethnicity and evaluated for demographics, comorbidities, and outcomes. Primary end point was 1-year AFS (above-ankle or greater). Noninferiority analysis was performed with the margin set at a hazard ratio of 1.297.
Results: There were 37 non-Caucasian patients (9 placebo, 28 cBMA) with "no surgical option" CLI randomized to placebo or cBMA at a 1:3 ratio during the MOBILE trial. There was no difference in outcomes between the ethnic minority (African Americans, Hispanics, others) and the Caucasian population (Fig) . At the 1-year follow-up mark for the treatment group, overall AFS was 84%. Of the 28 minorities randomized to cBMA intervention, 25 (89%) survived amputation free compared to a rate of 82% in Caucasians, and 22 of 24 (92%) African Americans survived amputation free at 1-year follow-up. Noninferiority testing confirmed no difference in cBMA-treated patients by ethnicity when looking at amputation risk reduction; however, the null hypothesis could not be rejected when looking at AFS. No significant differences were noted when comparing cBMA treated patients by ethnicity in terms of quality of life, pain, ankle-brachial index, toebrachial index, transcutaneous pressure of oxygen, and 6-minute walk testing.
Conclusions: The MOBILE trial demonstrates noninferiority of cBMA intervention in minorities with "no option" CLI for amputation risk prevention. cBMA, therefore, represents a novel treatment option and should be aggressively explored for minorities who face impending amputation secondary to progressive, end-stage CLI. Objectives: On behalf of Zorro Collaborators. This is a preliminary report of an Italian Multicenter Registry "the ZORRO (ZilverÒ PTXÒ Observational Registry on Recanalization for Obstructive disease) trial." Aim of the study is to evaluate the effectiveness of the Zilver PTX in superficial femoral artery (SFA) treatment, in patients with critical limb ischemia (CLI).
Methods: All patients treated with the drug-eluting stent (Zilver PTX, Cook Medical) were enrolled from 12 different Italian vascular centers and prospectively included in a registry lasting from the October 1, 2013, to August 30, 2015. Inclusion criteria were patients with CLI (Rutherford >3) and reference vessel diameters of 4 to 9 mm. Multilevel disease, as iliac or tibial involvement and treatment, did not represent an exclusion criteria. Outcomes evaluated in this report were 12-month patency rate (PR) and amputation free survival rate (LS) and estimated 24-month PR and LS.
Results: Seventy-five patients were recorded in the registry. Forty-three patients presented TASC C and D lesions, 59 received a primary treatment, and 16 had previous endovascular or surgical treatment of the reference vessel. Median length of the lesion was 10.7 cm (range 1-33 cm). No patients were lost at follow-up. All patients reached 12 months of follow-up and 25 patients reached 24 months. PR and LS at 12 months of follow-up were 93.3% and 93.3%, respectively, and at 24 months of follow-up were 84.9% and 94.6%, respectively. Thirteen patients required reinterventions at 12 months; however we observed only three stent occlusions, and the treatment in two cases was addressed only to tibial vessels.
Conclusions: This preliminary data encourage wise use of the drugeluting stent in SFA for CLI treatment. Zilver PTX seems to provide durable and effective treatment for SFA. Longer follow-up data are needed to confirm these preliminary findings.
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